Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy.

Lung cancer ipilimumab nivolumab pembrolizumab performance status

Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 05 10 2023
revised: 19 11 2023
accepted: 05 12 2023
medline: 1 3 2024
pubmed: 1 3 2024
entrez: 29 2 2024
Statut: ppublish

Résumé

Combined therapy with immune checkpoint inhibitors plus platinum doublet chemotherapy has a survival advantage over platinum doublet chemotherapy in patients with non-small cell lung cancer. However, a variety of factors make it difficult to administer treatment with platinum doublet chemotherapy in many patients in clinical practice and there are few reports on the efficacy and safety of first-line treatments with immune checkpoint inhibitors for patients who are ineligible for platinum doublet chemotherapy. This observational study aimed to evaluate the efficacy and safety of first-line immune checkpoint inhibitor therapy for this population. We retrospectively assessed the survival and adverse events from the initiation of first-line immune checkpoint inhibitor therapy, including pembrolizumab or nivolumab plus ipilimumab in patients with non-small cell lung cancer who were ineligible for platinum doublet chemotherapy. Data from 48 patients were analyzed. Seventeen patients showed a performance status (PS) of ≥2 while 16 and 15 patients were considered ineligible for platinum doublet chemotherapy because of age and comorbidities, respectively. The median (95% confidential interval, CI) progression-free survival (PFS) and overall survival (OS) of the 48 patients were 7.1 (1.7-13.7) and 31.7 (8.8-not estimated) months, respectively. The two-year PFS and OS rates (95% CI) were 30.8% (18.2%-47.2%) and 50.7% (33.7%-67.7%), respectively. In patients with a PS of ≥2, the median (95% CI) PFS and OS were 1.6 (1.2-not estimated) and 5.5 (2.3-not estimated) months, respectively. The two-year PFS and OS rates (95% CI) were 34.3% (15.8%-59.2%) and 45.3% (22.2%-70.7%), respectively. Patients with non-small cell lung cancer and a PS of 0-1 who were ineligible for platinum doublet chemotherapy had favorable outcome after the initiation of ICI therapy, and even in patients with a PS of ≥2, they achieved high two-year PFS and OS rates.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Combined therapy with immune checkpoint inhibitors plus platinum doublet chemotherapy has a survival advantage over platinum doublet chemotherapy in patients with non-small cell lung cancer. However, a variety of factors make it difficult to administer treatment with platinum doublet chemotherapy in many patients in clinical practice and there are few reports on the efficacy and safety of first-line treatments with immune checkpoint inhibitors for patients who are ineligible for platinum doublet chemotherapy. This observational study aimed to evaluate the efficacy and safety of first-line immune checkpoint inhibitor therapy for this population.
PATIENTS AND METHODS METHODS
We retrospectively assessed the survival and adverse events from the initiation of first-line immune checkpoint inhibitor therapy, including pembrolizumab or nivolumab plus ipilimumab in patients with non-small cell lung cancer who were ineligible for platinum doublet chemotherapy.
RESULTS RESULTS
Data from 48 patients were analyzed. Seventeen patients showed a performance status (PS) of ≥2 while 16 and 15 patients were considered ineligible for platinum doublet chemotherapy because of age and comorbidities, respectively. The median (95% confidential interval, CI) progression-free survival (PFS) and overall survival (OS) of the 48 patients were 7.1 (1.7-13.7) and 31.7 (8.8-not estimated) months, respectively. The two-year PFS and OS rates (95% CI) were 30.8% (18.2%-47.2%) and 50.7% (33.7%-67.7%), respectively. In patients with a PS of ≥2, the median (95% CI) PFS and OS were 1.6 (1.2-not estimated) and 5.5 (2.3-not estimated) months, respectively. The two-year PFS and OS rates (95% CI) were 34.3% (15.8%-59.2%) and 45.3% (22.2%-70.7%), respectively.
CONCLUSION CONCLUSIONS
Patients with non-small cell lung cancer and a PS of 0-1 who were ineligible for platinum doublet chemotherapy had favorable outcome after the initiation of ICI therapy, and even in patients with a PS of ≥2, they achieved high two-year PFS and OS rates.

Identifiants

DOI: 10.21873/anticanres.16920 PMID: 38423671
pubmed: 38423671
pii: 44/3/1241
doi: 10.21873/anticanres.16920
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1241-1245

Informations de copyright

Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Minehiko Inomata (M)

First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan; 9446-tym@umin.org.

Shuhei Minatoyama (S)

First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.

Naoki Takata (N)

First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.

Kana Hayashi (K)

First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.

Takahiro Hirai (T)

First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.

Zenta Seto (Z)

First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.

Kotaro Tokui (K)

First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.

Chihiro Taka (C)

First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.

Seisuke Okazawa (S)

First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.

Kenta Kambara (K)

First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.

Shingo Imanishi (S)

First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.

Toshiro Miwa (T)

First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.

Kei Matsuyama (K)

Department of Japanese Orient Medicine, Toyama University Hospital, Toyama, Japan.

Ryuji Hayashi (R)

Department of Medical Oncology, Toyama University Hospital, Toyama, Japan.

Shoko Matsui (S)

First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.

Kazuyuki Tobe (K)

First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.

Classifications MeSH